All In Biotech

NDA 019797 · Azurity

Nulytely

Polyethylene Glycol 3350, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride · Oral · Osmotic Laxative

Last checked: Nov 19, 2026Latest source record: May 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Apr 22, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

31 Phase 3, 9 recruiting

FAERS reports

248

151 serious, 30 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy in adults and pediatric patients aged 6 months or greater ( 1 )

Mechanism: The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • NULYTELY · POLYETHYLENE GLYCOL 3350 420GM/BOT; POTASSIUM CHLORIDE 1.48GM/BOT; SODIUM BICARBONATE 5.72GM/BOT; SODIUM CHLORIDE 11.2GM/BOT · FOR SOLUTION, ORAL · Prescription · TE AA
  • NULYTELY-FLAVORED · POLYETHYLENE GLYCOL 3350 420GM/BOT; POTASSIUM CHLORIDE 1.48GM/BOT; SODIUM BICARBONATE 5.72GM/BOT; SODIUM CHLORIDE 11.2GM/BOT · FOR SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Polyethylene Glycol 3350" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting34
  • nausea28
  • drug ineffective14
  • fatigue14
  • pneumonia14
  • chronic kidney disease13
  • abdominal distension12
  • renal failure12
  • asthenia11
  • constipation11
  • diarrhoea11
  • dyspnoea11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20061
20071
20081
20093
20102
20117
20122
201317
20145
201516
201619
201724
201829
201923
202024
20217
202225
20239
202415
202516

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nulytely (Sodium Chloride/NaHCO3/KCl/PEG)

2024 spending

$619

Beneficiaries

32

32 claims

Per beneficiary

$19

$0.00 per unit

View as table
YearSpending
2020$47,996
2021$145,943
2022$69,425
2023$2,220
2024$619

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 54 on PubMed

Sponsor: Azurity · Also marketed as Nulytely-Flavored

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.